E-ISSN: 2619-9467

Contents    Cover    Publication Date: 20 Sep 2023
Year 2023 - Volume 33 - Issue 3

Open Access

Peer Reviewed

767 Viewed569 Downloaded

Clinicopathological Characteristics and Survival Outcome in Uterine and Ovarian Carcinosarcomas: A Comparative Study

Full Text PDF  
JCOG. 2023;33(3):165-71
DOI: 10.5336/jcog.2022-94995
Article Language: EN
Copyright Ⓒ 2020 by Türkiye Klinikleri. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
Objective: Female genital system carcinosarcomas are rare gynecologic diseases that most commonly involve the corpus uteri. This study aimed to investigate the differences between uterine and ovarian carcinosarcomas in terms of histological, clinicopathological, and survival characteristics and evaluate the adjuvant treatment options received by patients, particularly at the sites of the first relapse. Material and Method: This retrospective study was conducted on patients with the diagnosis of uterine carcinosarcomas and ovarian carcinosarcomas treated between January 1, 2006, and December 31, 2020. Records of 54 patients (42 patients with uterine carcinosarcoma and 12 patients with ovarian carcinosarcoma) who underwent debulking surgery were analyzed. Results: No difference was found in terms of mean tumor diameter, lymphovascular space invasion, lymph node involvement, and omental assessment. Recurrence occurred in 18 patients with uterine carcinosarcoma and eight patients with ovarian carcinosarcoma. Distant organ metastases such as lung or brain were not detected in any of the patients during the follow-ups. Kaplan'Meier analysis showed that disease-free survival (DFS) and overall survival (OS) in the uterine carcinosarcoma and ovarian carcinosarcoma groups were similar (p=0 .938 for OS and p=0.328 for DFS). Conclusion: Ovarian carcinosarcomas can be seen at an earlier age than uterine carcinosarcomas, and it has fewer signs that may indicate disease. It should be underlined that 41.7% of patients with ovarian carcinosarcoma were in the premenopausal period.
  1. Schipf A, Mayr D, Kirchner T, Diebold J. Molecular genetic aberrations of ovarian and uterine carcinosarcomas--a CGH and FISH study. Virchows Arch. 2008;452(3):259-68. [Crossref]  [PubMed] 
  2. Amant F, Vloeberghs V, Woestenborghs H, Moerman P, Vergote I. Transition of epithelial toward mesenchymal differentiation during ovarian carcinosarcoma tumorigenesis. Gynecol Oncol. 2003;90(2):372-7. [Crossref]  [PubMed] 
  3. Jonson AL, Bliss RL, Truskinovsky A, Judson P, Argenta P, Carson L, et al. Clinical features and outcomes of uterine and ovarian carcinosarcoma. Gynecol Oncol. 2006;100(3):561-4. [Crossref]  [PubMed] 
  4. Nemani D, Mitra N, Guo M, Lin L. Assessing the effects of lymphadenectomy and radiation therapy in patients with uterine carcinosarcoma: a SEER analysis. Gynecol Oncol. 2008;111(1):82-8. [Crossref]  [PubMed] 
  5. Brown E, Stewart M, Rye T, Al-Nafussi A, Williams AR, Bradburn M, et al. Carcinosarcoma of the ovary: 19 years of prospective data from a single center. Cancer. 2004;100(10):2148-53. [Crossref]  [PubMed] 
  6. Cicin I, Saip P, Eralp Y, Selam M, Topuz S, Ozluk Y, et al. Ovarian carcinosarcomas: clinicopathological prognostic factors and evaluation of chemotherapy regimens containing platinum. Gynecol Oncol. 2008;108(1):136-40. [Crossref]  [PubMed] 
  7. Höhn AK, Brambs CE, Hiller GGR, May D, Schmoeckel E, Horn LC. 2020 WHO Classification of Female Genital Tumors. Geburtshilfe Frauenheilkd. 2021;81(10):1145-53. [Crossref]  [PubMed]  [PMC] 
  8. Barnholtz-Sloan JS, Morris R, Malone JM Jr, Munkarah AR. Survival of women diagnosed with malignant, mixed mullerian tumors of the ovary (OMMMT). Gynecol Oncol. 2004;93(2):506-12. [Crossref]  [PubMed] 
  9. Chang J, Sharpe JC, A'Hern RP, Fisher C, Blake P, Shepherd J, et al. Carcinosarcoma of the ovary: incidence, prognosis, treatment and survival of patients. Ann Oncol. 1995;6(8):755-8. [Crossref]  [PubMed] 
  10. Berton-Rigaud D, Devouassoux-Shisheboran M, Ledermann JA, Leitao MM, Powell MA, Poveda A, et al. Gynecologic Cancer InterGroup (GCIG) consensus review for uterine and ovarian carcinosarcoma. Int J Gynecol Cancer. 2014;24(9 Suppl 3):S55-60. [Crossref]  [PubMed] 
  11. Callister M, Ramondetta LM, Jhingran A, Burke TW, Eifel PJ. Malignant mixed Müllerian tumors of the uterus: analysis of patterns of failure, prognostic factors, and treatment outcome. Int J Radiat Oncol Biol Phys. 2004;58(3):786-96. [Crossref]  [PubMed] 
  12. Kehoe S, Bhatla N. FIGO Cancer Report 2021. Int J Gynaecol Obstet. 2021;155 Suppl 1:5-6. [Crossref]  [PubMed] 
  13. Matsuo K, Takazawa Y, Ross MS, Elishaev E, Podzielinski I, Yunokawa M, et al. Significance of histologic pattern of carcinoma and sarcoma components on survival outcomes of uterine carcinosarcoma. Ann Oncol. 2016;27(7):1257-66. [Crossref]  [PubMed] 
  14. Major FJ, Blessing JA, Silverberg SG, Morrow CP, Creasman WT, Currie JL, et al. Prognostic factors in early-stage uterine sarcoma. A Gynecologic Oncology Group study. Cancer. 1993;71(4 Suppl):1702-9. [Crossref]  [PubMed] 
  15. Ureyen I, Karalok A, Cirik DA, Tasci T, Gokce ZK, Duzguner IB, et al. Uterine and ovarian carcinosarcomas: do they behave similarly? J Obstet Gynaecol Can. 2017;39(7):559-63. [Crossref]  [PubMed] 
  16. Powell MA, Filiaci VL, Hensley ML, Huang HQ, Moore KN, Tewari KS, et al. Randomized phase III Trial of paclitaxel and carboplatin versus paclitaxel and ifosfamide in patients with carcinosarcoma of the uterus or ovary: an NRG oncology trial. J Clin Oncol. 2022;40(9):968-77. [Crossref]  [PubMed]  [PMC] 
  17. Galaal K, van der Heijden E, Godfrey K, Naik R, Kucukmetin A, Bryant A, et al. Adjuvant radiotherapy and/or chemotherapy after surgery for uterine carcinosarcoma. Cochrane Database Syst Rev. 2013;2013(2):CD006812. [PubMed]  [PMC] 
  18. Podoll MB, Moghadamfalahi M, Faber E, Bishop JA, Alatassi H. Sarcomatous component in uterine carcinosarcomas correlates with advanced stage and poorer prognosis. Int J Gynecol Pathol. 2018;37(1):22-6. [Crossref]  [PubMed]